Cargando…

Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression

SIMPLE SUMMARY: Different strategies have been explored to counteract immune evasion by shifting the balance in favor of antitumor immune activation, and combination cytotoxic chemotherapies have emerged as potent immune modulators for patients with low programmed death-ligand 1 expression. This stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Beung-Chul, Park, Charny, Lee, Sang-Jin, Hong, Sehwa, Hwang, Ji-Eun, Kwon, Kyoungsuk, Kim, Jin Young, Kim, Kyung-Hee, Kim, Hyae Young, Lee, Geon Kook, Lee, Youngjoo, Han, Ji-Youn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526182/ https://www.ncbi.nlm.nih.gov/pubmed/37760429 http://dx.doi.org/10.3390/cancers15184460

Ejemplares similares

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer
por: Yu, Namhee, et al.
Publicado: (2023)

A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation
por: Lee, Youngjoo, et al.
Publicado: (2022)

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Re-biopsy in Previously Treated Lung Cancer
por: Kim, Joohae, et al.
Publicado: (2019)

Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
por: Han, Ji-Youn, et al.
Publicado: (2015)

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2017)

Case of sclerosing pneumocytoma combined with a typical carcinoid and pulmonary adenocarcinoma in different lobes
por: Cho, Hwa Jin, et al.
Publicado: (2017)

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
por: Han, Ji-Youn, et al.
Publicado: (2017)

Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer
por: Kim, Hye Sook, et al.
Publicado: (2023)

Prognostic implications of PD-L1 expression in patients with angiosarcoma
por: Lee, Jii Bum, et al.
Publicado: (2021)

A Randomized Phase II Study of Irinotecan Plus Cisplatin with or without Simvastatin in Ever-Smokers with Extended Disease Small Cell Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2023)

A Case of Capecitabine-Induced Sarcoidosis
por: Kang, Shin Myung, et al.
Publicado: (2012)

Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer
por: Choi, Mihong, et al.
Publicado: (2021)

Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis
por: Jung, Jongheon, et al.
Publicado: (2021)

Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
por: Lee, Youngjoo, et al.
Publicado: (2017)

The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
por: Choi, Wonyoung, et al.
Publicado: (2021)

PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer
por: Han, Ji-Youn, et al.
Publicado: (2016)

Erratum to: PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer
por: Han, Ji-Youn, et al.
Publicado: (2016)

Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-Resistance
por: Kim, Jihyun, et al.
Publicado: (2023)

Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib
por: Kim, Hyojeong, et al.
Publicado: (2013)

A Case of Nivolumab-Induced Lichen Planus
por: Oh, Se Jin, et al.
Publicado: (2019)

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
por: Lim, Sun Min, et al.
Publicado: (2020)

Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma
por: Yun, Tak, et al.
Publicado: (2011)

ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer
por: Han, Ji-Youn, et al.
Publicado: (2017)

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
por: Yun, Tak, et al.
Publicado: (2016)

AFP-producing acinar cell carcinoma treated by pancreaticoduodenectomy in a patient with a previous radical subtotal gastrectomy by gastric cancer
por: Kim, Chang Young, et al.
Publicado: (2014)

Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
por: Ahn, Beung-Chul, et al.
Publicado: (2019)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
por: Heo, Mi Hwa, et al.
Publicado: (2019)

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
por: Boku, Narikazu, et al.
Publicado: (2021)

Prediction of Fractional Flow Reserve without Hyperemic Induction Based on Resting Baseline Pd/Pa
por: Kim, Jeong Su, et al.
Publicado: (2013)

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Impact of Nonselective and Selective α−1 Adrenergic Blockers on the Sedative Efficacy of Dexmedetomidine in Urologic Surgery: A Prospective, Observational Study
por: Baik, Jiseok, et al.
Publicado: (2023)

Fabry disease previously diagnosed as Henoch-Schonlein purpura
por: Kim, Ji Hyeong, et al.
Publicado: (2015)

A Study of 57 Patients with Prostate Cancer to Compare Outcomes of Estimated Blood Loss and Postoperative Pain Between Robot-Assisted Laparoscopic Radical Prostatectomy and Standard Laparoscopic Radical Prostatectomy
por: Hwang, Boo-young, et al.
Publicado: (2023)

Radiological Report of Pilot Study for the Korean Lung Cancer Screening (K-LUCAS) Project: Feasibility of Implementing Lung Imaging Reporting and Data System
por: Lee, Ji Won, et al.
Publicado: (2018)

Size-Specific Dose Estimation In the Korean Lung Cancer Screening Project: Does a 32-cm Diameter Phantom Represent a Standard-Sized Patient in Korean Population?
por: Kim, Eun Young, et al.
Publicado: (2018)

An association between colonic adenoma and abdominal obesity: a cross-sectional study
por: Kim, YoungJoo, et al.
Publicado: (2009)

Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
por: Sun, Young JUNG, et al.
Publicado: (2011)

Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

The EZ-Blocker(®) for one-lung ventilation in a patient with Kartagener syndrome and tracheal bronchus -a case report-
por: Hwang, Boo-young, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uohrpa0oo0rbmjtvpa6aanneh5